NASDAQ:AVDL Avadel Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avadel Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.88 -0.03 (-0.51 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$5.65Now: $5.88▼$6.1250-Day Range$5.25MA: $7.28▼$8.6452-Week Range$3.25Now: $5.88▼$13.49Volume2.46 million shsAverage Volume832,516 shsMarket Capitalization$220.21 millionP/E Ratio36.75Dividend YieldN/ABeta1.28 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.39, Avadel Pharmaceuticals has a forecasted upside of 161.7% from its current price of $5.88.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAvadel Pharmaceuticals has received 284 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAvadel Pharmaceuticals has received 296 “underperform” votes. (Add your “underperform” vote.)Community SentimentAvadel Pharmaceuticals has received 51.03% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote “Outperform” if you believe AVDL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $994,779.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.41% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions96.86% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to decrease in the coming year, from ($0.68) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is 36.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is 36.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.04. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.98 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVDL Previous Symbol CUSIPN/A CIK1012477 Webwww.avadel.com Phone011-1-485-1200Debt Debt-to-Equity Ratio0.69 Current Ratio10.25 Quick Ratio10.25Price-To-Earnings Trailing P/E Ratio36.75 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$59.22 million Price / Sales3.72 Cash FlowN/A Price / Cash FlowN/A Book Value($0.78) per share Price / Book-7.54Profitability EPS (Most Recent Fiscal Year)($0.89) Net Income$-33,230,000.00 Net Margins38.70% Return on Equity-69.24% Return on Assets-12.78%Miscellaneous Employees144 Outstanding Shares37,450,000Market Cap$220.21 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $5.88 -0.03 (-0.51 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AVDL News and Ratings via Email Sign-up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions How has Avadel Pharmaceuticals' stock price been impacted by Coronavirus? Avadel Pharmaceuticals' stock was trading at $7.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AVDL shares have decreased by 26.4% and is now trading at $5.88. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Avadel Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avadel Pharmaceuticals. When is Avadel Pharmaceuticals' next earnings date? Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Avadel Pharmaceuticals. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals PLC (NASDAQ:AVDL) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $10.09 million for the quarter, compared to analysts' expectations of $8.08 million. Avadel Pharmaceuticals had a net margin of 38.70% and a negative return on equity of 69.24%. View Avadel Pharmaceuticals' earnings history. What price target have analysts set for AVDL? 9 equities research analysts have issued twelve-month target prices for Avadel Pharmaceuticals' shares. Their forecasts range from $6.00 to $22.00. On average, they anticipate Avadel Pharmaceuticals' stock price to reach $15.39 in the next twelve months. This suggests a possible upside of 161.7% from the stock's current price. View analysts' price targets for Avadel Pharmaceuticals. Are investors shorting Avadel Pharmaceuticals? Avadel Pharmaceuticals saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 5,540,000 shares, an increase of 10.1% from the July 30th total of 5,030,000 shares. Based on an average trading volume of 663,400 shares, the short-interest ratio is presently 8.4 days. View Avadel Pharmaceuticals' Short Interest. Who are some of Avadel Pharmaceuticals' key competitors? Some companies that are related to Avadel Pharmaceuticals include Provention Bio (PRVB), Frequency Therapeutics (FREQ), VBI Vaccines (VBIV), Protagonist Therapeutics (PTGX), resTORbio (TORC), Kadmon (KDMN), Endo International (ENDP), Phibro Animal Health (PAHC), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), ImmunoGen (IMGN), Collegium Pharmaceutical (COLL), DiaMedica Therapeutics (DMCAF), Cara Therapeutics (CARA) and Omeros (OMER). View all competitors. What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), Chaarat Gold (CGH), Associated British Foods (ABF), AMC Entertainment (AMC), Apollo Global Management (APO), Cypress Semiconductor (CY) and First Data (FDC). Who are Avadel Pharmaceuticals' key executives? Avadel Pharmaceuticals' management team includes the following people: Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)Ms. Sandra L. Hatten, Sr. VP of Quality & Regulatory Affairs (Age 62)Mr. Gregory J. Divis Jr., Interim Chief Exec. Officer (Age 52) What is Avadel Pharmaceuticals' stock symbol? Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL." Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include RTW Investments LP (14.17%), Brandes Investment Partners LP (3.96%), Asymmetry Capital Management L.P. (1.42%), Ikarian Capital LLC (1.30%), Avidity Partners Management LP (1.22%) and Bailard Inc. (0.78%). Company insiders that own Avadel Pharmaceuticals stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh. View institutional ownership trends for Avadel Pharmaceuticals. Which major investors are selling Avadel Pharmaceuticals stock? AVDL stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Tekla Capital Management LLC, Brandes Investment Partners LP, and Blair William & Co. IL. View insider buying and selling activity for Avadel Pharmaceuticals. Which major investors are buying Avadel Pharmaceuticals stock? AVDL stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Asymmetry Capital Management L.P., Bailard Inc., Calamos Advisors LLC, Balyasny Asset Management LLC, Candriam Luxembourg S.C.A., Avidity Partners Management LP, and Russell Investments Group Ltd.. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, and Thomas S Mchugh. View insider buying and selling activity for Avadel Pharmaceuticals. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Avadel Pharmaceuticals' stock price today? One share of AVDL stock can currently be purchased for approximately $5.88. How big of a company is Avadel Pharmaceuticals? Avadel Pharmaceuticals has a market capitalization of $220.21 million and generates $59.22 million in revenue each year. The company earns $-33,230,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Avadel Pharmaceuticals employs 144 workers across the globe. What is Avadel Pharmaceuticals' official website? The official website for Avadel Pharmaceuticals is www.avadel.com. How can I contact Avadel Pharmaceuticals? Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The company can be reached via phone at 011-1-485-1200 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
